These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 22108801)
1. Reduced bone turnover in mice lacking the P2Y13 receptor of ADP. Wang N; Robaye B; Agrawal A; Skerry TM; Boeynaems JM; Gartland A Mol Endocrinol; 2012 Jan; 26(1):142-52. PubMed ID: 22108801 [TBL] [Abstract][Full Text] [Related]
2. Extracellular ADP is a powerful osteolytic agent: evidence for signaling through the P2Y(1) receptor on bone cells. Hoebertz A; Meghji S; Burnstock G; Arnett TR FASEB J; 2001 May; 15(7):1139-48. PubMed ID: 11344082 [TBL] [Abstract][Full Text] [Related]
3. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. Su X; Floyd DH; Hughes A; Xiang J; Schneider JG; Uluckan O; Heller E; Deng H; Zou W; Craft CS; Wu K; Hirbe AC; Grabowska D; Eagleton MC; Townsley S; Collins L; Piwnica-Worms D; Steinberg TH; Novack DV; Conley PB; Hurchla MA; Rogers M; Weilbaecher KN J Clin Invest; 2012 Oct; 122(10):3579-92. PubMed ID: 22996695 [TBL] [Abstract][Full Text] [Related]
4. Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes. Biver G; Wang N; Gartland A; Orriss I; Arnett TR; Boeynaems JM; Robaye B Stem Cells; 2013 Dec; 31(12):2747-58. PubMed ID: 23629754 [TBL] [Abstract][Full Text] [Related]
5. Macrophage migration inhibitory factor (MIF) inhibitor 4-IPP suppresses osteoclast formation and promotes osteoblast differentiation through the inhibition of the NF-κB signaling pathway. Zheng L; Gao J; Jin K; Chen Z; Yu W; Zhu K; Huang W; Liu F; Mei L; Lou C; He D FASEB J; 2019 Jun; 33(6):7667-7683. PubMed ID: 30893559 [TBL] [Abstract][Full Text] [Related]
7. Targeted overexpression of G protein-coupled receptor kinase-2 in osteoblasts promotes bone loss. Wang L; Liu S; Quarles LD; Spurney RF Am J Physiol Endocrinol Metab; 2005 Apr; 288(4):E826-34. PubMed ID: 15585587 [TBL] [Abstract][Full Text] [Related]
8. Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Sophocleous A; Marino S; Kabir D; Ralston SH; Idris AI Aging Cell; 2017 Oct; 16(5):1051-1061. PubMed ID: 28752643 [TBL] [Abstract][Full Text] [Related]
9. Liver X receptors orchestrate osteoblast/osteoclast crosstalk and counteract pathologic bone loss. Kleyer A; Scholtysek C; Bottesch E; Hillienhof U; Beyer C; Distler JH; Tuckermann JP; Schett G; Krönke G J Bone Miner Res; 2012 Dec; 27(12):2442-51. PubMed ID: 22806960 [TBL] [Abstract][Full Text] [Related]
10. A Novel Rhein Derivative Modulates Bone Formation and Resorption and Ameliorates Estrogen-Dependent Bone Loss. Jiang M; Wang T; Yan X; Liu Z; Yan Y; Yang K; Qi J; Zhou H; Qian N; Zhou Q; Chen B; Xu X; Xi X; Yang C; Deng L J Bone Miner Res; 2019 Feb; 34(2):361-374. PubMed ID: 30320929 [TBL] [Abstract][Full Text] [Related]
11. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Binder NB; Niederreiter B; Hoffmann O; Stange R; Pap T; Stulnig TM; Mack M; Erben RG; Smolen JS; Redlich K Nat Med; 2009 Apr; 15(4):417-24. PubMed ID: 19330010 [TBL] [Abstract][Full Text] [Related]
12. Role of purinergic receptor polymorphisms in human bone. Wesselius A; Bours MJ; Agrawal A; Gartland A; Dagnelie PC; Schwarz P; Jorgensen NR Front Biosci (Landmark Ed); 2011 Jun; 16(7):2572-85. PubMed ID: 21622196 [TBL] [Abstract][Full Text] [Related]
13. Adenosine A(1) receptors regulate bone resorption in mice: adenosine A(1) receptor blockade or deletion increases bone density and prevents ovariectomy-induced bone loss in adenosine A(1) receptor-knockout mice. Kara FM; Doty SB; Boskey A; Goldring S; Zaidi M; Fredholm BB; Cronstein BN Arthritis Rheum; 2010 Feb; 62(2):534-41. PubMed ID: 20112380 [TBL] [Abstract][Full Text] [Related]
14. The P2Y(6) receptor stimulates bone resorption by osteoclasts. Orriss IR; Wang N; Burnstock G; Arnett TR; Gartland A; Robaye B; Boeynaems JM Endocrinology; 2011 Oct; 152(10):3706-16. PubMed ID: 21828185 [TBL] [Abstract][Full Text] [Related]
15. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. Cheng X; Kinosaki M; Takami M; Choi Y; Zhang H; Murali R J Biol Chem; 2004 Feb; 279(9):8269-77. PubMed ID: 14679212 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-11 receptor signaling is required for normal bone remodeling. Sims NA; Jenkins BJ; Nakamura A; Quinn JM; Li R; Gillespie MT; Ernst M; Robb L; Martin TJ J Bone Miner Res; 2005 Jul; 20(7):1093-102. PubMed ID: 15940362 [TBL] [Abstract][Full Text] [Related]
17. Ablation of p38α MAPK Signaling in Osteoblast Lineage Cells Protects Mice From Bone Loss Induced by Estrogen Deficiency. Thouverey C; Caverzasio J Endocrinology; 2015 Dec; 156(12):4377-87. PubMed ID: 26441240 [TBL] [Abstract][Full Text] [Related]
18. Peripheral cannabinoid receptor, CB2, regulates bone mass. Ofek O; Karsak M; Leclerc N; Fogel M; Frenkel B; Wright K; Tam J; Attar-Namdar M; Kram V; Shohami E; Mechoulam R; Zimmer A; Bab I Proc Natl Acad Sci U S A; 2006 Jan; 103(3):696-701. PubMed ID: 16407142 [TBL] [Abstract][Full Text] [Related]
19. Bone phenotypes of P2 receptor knockout mice. Orriss I; Syberg S; Wang N; Robaye B; Gartland A; Jorgensen N; Arnett T; Boeynaems JM Front Biosci (Schol Ed); 2011 Jun; 3(3):1038-46. PubMed ID: 21622253 [TBL] [Abstract][Full Text] [Related]
20. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder. Sugatani T Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]